•
PD
PDSB
PDS Biotechnology Corporation Common Stock
polygonPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
51.77M
Volume
790.27K
52W High
$2.20
52W Low
$0.70
Open
$0.95
Prev Close
$0.95
Day Range
0.93 - 0.99
About PDS Biotechnology Corporation Common Stock
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Latest News
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
Benzinga•Jan 12
PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering
GlobeNewswire Inc.•Nov 11
PDSB Loss Improves as Costs Drop
The Motley Fool•Aug 13
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Dec 6
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation
GlobeNewswire Inc.•Oct 2
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024
GlobeNewswire Inc.•Sep 9
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
GlobeNewswire Inc.•May 9
PDS Biotechnology Announces Details of Virtual KOL Event
GlobeNewswire Inc.•May 3